New insider activity at Guardant Health ( (GH) ) has taken place on March 9, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Director Hidalgo Medina Manuel has offloaded 1,300 shares of Guardant Health in a recent transaction, with the sale totaling $118,990. This move reflects a notable insider sale by a member of the company’s board, providing investors with fresh insight into insider trading activity at Guardant Health.
Recent Updates on GH stock
Guardant Health shares reacted to a wave of bullish analyst commentary following its Q4 earnings, which showcased strong revenue growth, rising test volumes, and improving margins, especially in oncology and the Shield screening franchise. Multiple firms lifted price targets citing robust 2026 guidance, momentum across core therapy selection and MRD businesses, and a solid balance sheet, while also noting heavy but deliberate Shield investments and a catalyst-rich, though uncertain, regulatory and reimbursement backdrop.
Spark’s Take on GH Stock
According to Spark, TipRanks’ AI Analyst, GH is a Neutral.
The score is held back primarily by weak financial performance (large losses, ongoing cash burn, and balance-sheet strain with negative equity and higher debt). Offsetting this, the latest earnings call was constructive with strong 2026 growth guidance and improving cash burn trajectory, while technical signals are mixed-to-neutral and valuation remains challenged due to losses and no dividend support.
To see Spark’s full report on GH stock, click here.
More about Guardant Health
YTD Price Performance: -10.71%
Average Trading Volume: 1,979,851
Technical Sentiment Signal: Buy
Current Market Cap: $11.96B